Stock 2315 BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Equities

2315

CNE100005D27

Biotechnology & Medical Research

End-of-day quote Hong Kong S.E.
Other stock markets
 23:00:00 30/05/2024 BST 		5-day change 1st Jan Change
8.89 CNY +1.95% Intraday chart for Biocytogen Pharmaceuticals (Beijing) Co., Ltd. -7.01% -25.79%
05-06 Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies CI
04-26 Biocytogen Pharmaceuticals' Loss Narrows in 2023 MT

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 9,048 4,349 3,288 - -
Enterprise Value (EV) 1 8,836 4,475 3,422 3,224 2,882
P/E ratio -14.3 x -11.3 x -37.4 x 34.3 x 17.9 x
Yield - - - - -
Capitalization / Revenue 16.9 x 6.07 x 3.58 x 2.87 x 2.38 x
EV / Revenue 16.6 x 6.24 x 3.72 x 2.82 x 2.08 x
EV / EBITDA -19.8 x -33.1 x 41.2 x 12.8 x 6.34 x
EV / FCF -16,257,344 x - - - -
FCF Yield -0% - - - -
Price to Book 7.89 x - - - -
Nbr of stocks (in thousands) 399,398 399,398 399,398 - -
Reference price 2 22.65 10.89 8.233 8.233 8.233
Announcement Date 27/03/23 27/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 354.6 533.9 716.9 919.3 1,145 1,383
EBITDA 1 - -447 -135.1 83.06 252.4 454.8
EBIT 1 - -621.1 -317.4 -98.43 94.9 250.7
Operating Margin - -116.33% -44.28% -10.71% 8.29% 18.14%
Earnings before Tax (EBT) 1 - -601.4 -380.2 -89 115 214
Net income 1 -545.6 -601.9 -383 -89 98 182
Net margin -153.88% -112.75% -53.42% -9.68% 8.56% 13.16%
EPS 2 - -1.580 -0.9600 -0.2200 0.2400 0.4600
Free Cash Flow - -543.5 - - - -
FCF margin - -101.81% - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 - - - - - -
Announcement Date 19/08/22 27/03/23 27/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 304.8 326.8 390.1 396.5 527
EBITDA - - - - -
EBIT -328.4 - -157.8 - -
Operating Margin -107.75% - -40.45% - -
Earnings before Tax (EBT) - - - - -
Net income - - - - -
Net margin - - - - -
EPS - - - - -
Dividend per Share - - - - -
Announcement Date 27/03/23 26/09/23 27/03/24 - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt 1 - - 126 133 - -
Net Cash position 1 - 211 - - 64.3 406
Leverage (Debt/EBITDA) - - -0.9358 x 1.606 x - -
Free Cash Flow - -544 - - - -
ROE (net income / shareholders' equity) - -50.3% - -12.7% 12.3% 18.6%
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share - 2.870 - - - -
Cash Flow per Share - -0.8000 - - - -
Capex 1 - 240 - - - -
Capex / Sales - 45% - - - -
Announcement Date 19/08/22 27/03/23 27/03/24 - - -
1CNY in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
8.233 CNY
Average target price
14.21 CNY
Spread / Average Target
+72.66%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. Stock Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
-25.79% 454M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.64B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
LONZA GROUP AG Stock Lonza Group AG
+37.52% 38.82B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. 2315 Stock
  4. Financials Biocytogen Pharmaceuticals (Beijing) Co., Ltd.